Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2004;2004(3):CD000058.
doi: 10.1002/14651858.CD000058.pub2.

Clonidine for smoking cessation

S G Gourlay  1 , L F Stead, N L Benowitz
Affiliations
Meta-Analysis

Clonidine for smoking cessation

S G Gourlay et al. Cochrane Database Syst Rev. 2004.

Abstract

Background: Clonidine was originally used to lower blood pressure. It acts on the central nervous system and may reduce withdrawal symptoms in various addictive behaviours, including tobacco use.

Objectives: The aim of this review is to determine clonidine's effectiveness in helping smokers to quit.

Search strategy: We searched the Cochrane Tobacco Addiction Group trials register for trials of clonidine. Date of the most recent search: May 2004.

Selection criteria: We considered randomized trials of clonidine versus placebo with a smoking cessation endpoint assessed at least 12 weeks following the end of treatment.

Data collection and analysis: We extracted data in duplicate on the type of subjects, the dose and duration of clonidine therapy, the outcome measures, method of randomization, and completeness of follow up. The main outcome measure was abstinence from smoking after at least 12 weeks follow up in patients smoking at baseline. We used the most rigorous definition of abstinence for each trial, and biochemically validated rates if available. Where appropriate, we performed meta-analysis using a fixed effect model.

Main results: Six trials met the inclusion criteria. There were three trials of oral, and three of transdermal clonidine. Some form of behavioural counselling was offered to all participants in five of the six trials. There was a statistically significant effect of clonidine in one of these trials. The pooled odds ratio for success with clonidine versus placebo was 1.89 (95% confidence interval 1.30 to 2.74). There was a high incidence of dose-dependent side-effects, particularly dry mouth and sedation.

Reviewers' conclusions: Based on a small number of trials, in which there are potential sources of bias, clonidine is effective in promoting smoking cessation. Prominent side-effects limit the usefulness of clonidine for smoking cessation.

PubMed Disclaimer

Conflict of interest statement

Steven Gourlay received grant support 1990‐1994 from makers of nicotine replacement therapies and clonidine. Neal Benowitz is a consultant to various pharmaceutical companies that manufacture and/or market nicotine replacement products.

Figures

1.1
1.1. Analysis
Comparison 1 Clonidine vs placebo, Outcome 1 Smoking Cessation.
See this image and copyright information in PMC

Update of

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Glassman 1988 {published data only}
    1. Glassman AH, Stetner F, Walsh T, Raizman PS, Fleiss J, Cooper TB, et al. Heavy smokers, smoking cessation, and clonidine. Results of a double‐blind, randomized trial. JAMA 1988;259:2863‐6. - PubMed
Glassman 1993 {published and unpublished data}
    1. Glassman AH, Covey LS, Dalack GW, Stetner F, Rivelli SK, Fleiss J, et al. Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers. Clinical Pharmacology and Therapeutics 1993;54:670‐9. - PubMed
Hao 1988 {published data only}
    1. Hao‐W, Young D, Wei H. Effect of clonidine on cigarette cessation and in the alleviation of withdrawal symptoms [published erratum appears in British Journal of Addiction 1988;83:1467]. British Journal of Addiction 1988;83:1221‐6. - PubMed
Hilleman 1993 {published data only}
    1. Hilleman DE, Mohiuddin SM, Delcore MG, Lucas BD. Randomized, controlled trial of transdermal clonidine for smoking cessation. The Annals of Pharmacotherapy 1993;27:1025‐8. - PubMed
Niaura 1996 {published data only}
    1. Niaura R, Brown RA, Goldstein MG, Murphy JK, Abrams DB. Transdermal clonidine for smoking cessation ‐ a double‐blind randomized dose‐response study. Experimental and Clinical Psychopharmacology 1996;4:285‐91.
Villagra 1989 {published and unpublished data}
    1. Villagra VG. Transdermal clonidine for smoking cessation: a randomized trial. Clinical Research 1991;39:640A.
    1. Villagra VG, Rosenberger JL, Girolami S. Transdermal clonidine for smoking cessation: A randomized, double blind, placebo controlled trial. Circulation 1989;80 Suppl II(4):11‐58.

References to studies excluded from this review

Ahmadi 2003 {published data only}
    1. Ahmadi J, Ashkani H, Ahmadi M, Ahmadi N. Twenty‐four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone. Journal of Substance Abuse Treatment 2003;24:251‐5. - PubMed
Aparici 1994 {published data only}
    1. Aparici M, Fernandez Gonzalez AL, Alegria E. Clonidine in the treatment of tobacco withdrawal. Comparison with nicotine chewing gum [Clonidina en el tratamiento de la deshabituacion tabaquica. Comparacion con chicles de nicotina.]. Revista Clinica Espanol 1994;194:453‐6. - PubMed
Appel 1987 {published data only}
    1. Appel D. Clonidine helps cigarette smokers stop smoking. American Review of Respiratory Diseases 1987;135(Suppl):A354.
Cummings 1991 {unpublished data only}
    1. Cummings KM. A double‐blind placebo controlled multi‐center trial of two dosage strengths of Catapres‐TTS in smoking cessation. Unpublished draft manuscript.
Davison 1988 {published data only}
    1. Davison R, Kaplan K, Fintel D, Parker M, Anderson L, Haring O. The effect of clonidine on the cessation of cigarette smoking. Clinical Pharmacology and Therapeutics 1988;44:265‐7. - PubMed
Franks 1989 {published data only}
    1. Franks P, Harp J, Bell B. Randomized, controlled trial of clonidine for smoking cessation in a primary care setting [comment in: JAMA 1990 May 23‐30;263(20):2746‐7]. JAMA 1989;262:3011‐3. - PubMed
Glassman 1984 {published data only}
    1. Glassman AH, Jackson WK, Walsh BT, Roose SP, Rosenfeld B. Cigarette craving, smoking withdrawal, and clonidine. Science 1984;226:864‐6. - PubMed
Gourlay 1994 {published data only}
    1. Gourlay SG, Forbes A, Marriner T, Kutin J, McNeil J. A placebo‐controlled study of three clonidine doses for smoking cessation. Clinical Pharmacology and Therapeutics 1994;55:64‐9. - PubMed
Grimaldi 1987 {published data only}
    1. Grimaldi B, Demaria C, Loufrani E, Bang F, Geslin P, Lagrue G. Results of a controlled study of clonidine vs placebo for cessation of smoking [Résultats d'une étude controlée clonidine/placebo dans le sevrage tabagique]. Sem Hop Paris 1987;63:3369‐70.
Hilleman 1989 {published data only}
    1. Hilleman DE, Mohiuddin SM, Malesker MA, Delcore MG, Sketch MH. Double‐blind, placebo‐controlled evaluation of transdermal clonidine in smoking cessation. Chest 1989;96(Suppl):208S.
Murray 1989 {published data only}
    1. Murray KM, Cappello C, Baez SA. Lack of efficacy of transdermal clonidine in a smoking cessation class. American Review of Respiratory Diseases 1989;139(Suppl):A338.
Nana 1998 {published data only}
    1. Nana A, Praditsuwan R. Clonidine for smoking cessation. Journal of the Medical Association of Thailand 1998;81:87‐93. - PubMed
Ornish 1988 {published data only}
    1. Ornish SA, Zisook S, McAdams LA. Effects of transdermal clonidine treatment on withdrawal symptoms associated with smoking cessation. A randomized, controlled trial. Archives of Internal Medicine 1988;148:2027‐31. - PubMed
Prochazka 1992 {published data only}
    1. Prochazka AV, Petty TL, Nett L, Silvers GW, Sachs DPL, Rennard SI, et al. Transdermal clonidine reduced some withdrawal symptoms but did not increase smoking cessation. Archives of Internal Medicine 1992;152:2065‐9. - PubMed
Wu 1997 {published data only}
    1. Wu Gue‐qang, et al. 'Effects of transcutaneous clonidine refraining of the nicotine addiction' [poster 311]. Abstracts of the 10th World Conference on Tobacco or Health; Aug 24‐28; Beijing, China. 1997:208.

Additional references

Bredfeldt 1989
    1. Bredfeldt RC, Sutherland JE, Kruse JE. Efficacy of transdermal clonidine for headache prophylaxis and reduction of narcotic use in migraine patients. Journal of Family Practice 1989;29:153‐6. - PubMed
Edington 1980
    1. Edington RF, Chagnon J‐P, Steinburg WM. Clonidine (dixarit) for menopausal flushing. Canadain Medical Association Journal 1980;123:23‐5. - PMC - PubMed
Ginsburg 1985
    1. Ginsburg J, O’Reilly B, Swinhoe J. Effect of oral clonidine on human cardiovascular responsiveness: a possible explanation of the therapeutic action of the drug in menopausal flushing and migraine. British Journal of Obstetrics and Gynaecology 1985;92:1169‐75. - PubMed
Gold 1993
    1. Gold MS. Opiate addiction and the locus coeruleus: The clinical utility of clonidine, naltrexone, methadone, and buprenorphine. The Psychiatric Clinics of North America 1993;16:61‐73. - PubMed
Gourlay 1994a
    1. Gourlay SG, Forbes A, Marriner T, Kutin J, McNeil J. A placebo‐controlled study of three clonidine doses for smoking cessation. Clinical Pharmacology and Therapeutics 1994;55:64‐9. - PubMed
Gourlay 1995
    1. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy?. Drugs 1995;50:197‐207. [MEDLINE: ] - PubMed
Hughes 2007
    1. Hughes JR, Stead LF, Lancaster T. Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD000031.pub3] - DOI - PubMed
ICRF GPRG 1993
    1. Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomised trial in general practice. BMJ 1993;306:1304‐8. - PMC - PubMed
Leckman 1985
    1. Leckman JF, Detlor J, Harcherik DF, Ort S, Shaywitz BA, Cohen DJ. Short‐ and long‐term treatment of Tourette’s syndrome with clonidine: a clinical perspective. Neurology 1985;35:343‐51. - PubMed
Manhem 1985
    1. Manhem P, Nilsson LH, Moberg A, Wadstein J, Hokfelt B. Alcohol withdrawal: effects of clonidine treatment on sympathetic activity, the renin‐aldosterone system, and clinical symptoms. Alcoholism, Clinical and Experimental Research 1985;9:238‐43. - PubMed
Russell 1993
    1. Russell MAH, Stapleton JA, Feyerabend C, Wiseman SM, Gustavsson G, Saw U, Connor P. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. BMJ 1993;306:1308‐12. - PMC - PubMed
Stead 2008
    1. Stead LF, Perera R, Bullen C, Mant D, Lancaster T. Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD000146.pub3] - DOI - PubMed
TNSG 1991
    1. Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Six‐month results from two multicenter controlled clinical trials. JAMA 1991;266:3133‐8. [MEDLINE: ] - PubMed
US DHHS 1988
    1. U.S. Department of Health and Human Services. The Health Consequences of Smoking ‐ Nicotine Addiction: A report of the Surgeon General. US DHHS, 1988.

References to other published versions of this review

Gourlay 1997
    1. Gourlay SG, Stead LF, Benowitz NL. A meta‐analysis of clonidine for smoking cessation. Cochrane Database of Systematic Reviews 1997, Issue 1.
Gourlay 2001
    1. Gourlay SG, Stead LF, Benowitz NL. Clonidine for smoking cessation. Cochrane Database of Systematic Reviews 2001, Issue 4.